Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
The present disclosure relates to antisense oligonucleotides (AONs) for modulating the expression of glycogen synthase. AONs of the present disclosure may be useful in treating diseases associated with the modulation of the expression of the enzyme glycogen synthase, such as Pompe disease. Also provided by the present disclosure are compositions comprising AONs, as well as methods of down regulating mRNA coding for glycogen synthase, methods for reducing glycogen synthase in skeletal and cardiac muscle, and methods for treating Pompe disease.
1. A method of down regulating mRNA coding for glycogen synthase comprising administering an effective amount of an antisense oligonucleotide to an animal, wherein the antisense oligonucleotide comprises a sequence at least 85% complementary to a nucleic acid sequence at the exon-intron boundary of exon 5 or exon 6 of a pre-messenger RNA (pre-mRNA) encoding for glycogen synthase isoform 1 (GYS1), and wherein the hybridization of the antisense oligonucleotide to the nucleic acid sequence induces exon skipping.
2. The method of claim 1 , wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligo (PMO).
3. The method of claim 1 , wherein the antisense oligonucleotide is a PMO linked to a cell penetrating peptide (CPP).
4. The method of claim 1 , wherein the antisense oligonucleotide is selected from an oligonucleotide comprising subunits of one of Formula I-VI:
wherein B in each of Formula I-VI is a nucleotide base.
5. The method of claim 1 , wherein mRNA coding for glycogen synthase is reduced by 80%.
6. The method of claim 1 , wherein mRNA coding for glycogen synthase is reduced by 90%.
7. The method of claim 1 , wherein mRNA coding for glycogen synthase is reduced by 95%.
8. The method of claim 1 , wherein the effective amount ranges from 5 to 500 mg per dose.
9. The method of claim 1 , wherein the compound is administered intravenously.
10. The method of claim 1 , wherein the down regulation of mRNA coding for glycogen synthase occurs in skeletal and cardiac muscle.
11. The method of claim 1 , wherein the antisense oligonucleotide is at least 90% complementary to the nucleic acid sequence.
12. The method of claim 1 , wherein the antisense oligonucleotide is at least 95% complementary to the nucleic acid sequence encoding.
13. A method for reducing glycogen synthase in skeletal and cardiac muscle comprising administering to an animal an effective amount of an antisense oligonucleotide to an animal, wherein the antisense oligonucleotide comprises a sequence at least 85% complementary to a nucleic acid sequence at the exon-intron boundary of exon 5 or exon 6 of a pre-mRNA encoding for glycogen synthase isoform 1 (GYS1), and wherein the hybridization of the antisense oligonucleotide to the nucleic acid sequence induces exon skipping.
14. A method for treating Pompe disease comprising administering to an animal an effective amount of an antisense oligonucleotide to an animal, wherein the antisense oligonucleotide comprises a sequence at least 85% complementary to a nucleic acid sequence at the exon-intron boundary of exon 5 or exon 6 of a pre-mRNA encoding for glycogen synthase isoform 1 (GYS1), and wherein the hybridization of the antisense oligonucleotide to the nucleic acid sequence induces exon skipping.
15. The method of claim 1 , wherein the nucleic acid sequence is at the exon-intron boundary of exon 5 of a pre-mRNA encoding for GYS1.
16. The method of claim 15 , wherein the antisense oligonucleotide comprises the nucleic acid sequence of SEQ ID NO: 62.
17. The method of claim 1 , wherein the nucleic acid sequence is at the exon-intron boundary of exon 6 of a pre-mRNA encoding for GYS1.
18. The method of claim 17 , wherein the antisense oligonucleotide comprises the nucleic acid sequence of SEQ ID NO: 63.
19. The method of claim 1 , wherein the level of glycogen synthase isoform 2 (GYS2) in the liver does not change significantly.
20. The method of claim 1 , wherein the effective amount is about 15 mg/kg or about 30 mg/kg.